Inventor · disambiguated record
Kathleen E. Clarence-Smith
Also filed as: CLARENCE-SMITH KATHLEEN · CLARENCE-SMITH KATHLEEN E
33 granted patents·31 pending applications·109 citations·filing 2003–2025
96Inventor score
Files withCHASE PHARMACEUTICALS CORP25CHASE THERAPEUTICS CORP18DAS MG INC8CHASE THOMAS N4AVION PHARMACEUTICALS LLC3
Top patents by PatentIndex Score
64 records- 0193US9278092B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Mar 8, 2016·17 cites·14 claims
- 0293US8404701B2Use and composition for treating dementiaCHASE THOMAS N·Filed 2009·Granted Mar 26, 2013·24 cites·13 claims
- 0392US9561218B2Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2013·Granted Feb 7, 2017·17 cites·3 claims
- 0492US8877768B2Method and composition for treating alzheimer-type dementiaCHASE THOMAS N·Filed 2010·Granted Nov 4, 2014·18 cites·14 claims
- 0589US11160809B2NK1-antagonist combination and method for treating synucleinopathiesCHASE THERAPEUTICS CORP·Filed 2018·Granted Nov 2, 2021·4 cites·23 claims
- 0687US11266633B2NK-1 antagonist compositions and methods for use in treating depressionCHASE THERAPEUTICS CORP·Filed 2018·Granted Mar 8, 2022·5 cites·10 claims
- 0785US9192591B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Nov 24, 2015·3 cites·22 claims
- 0884US11547700B2Compositions and methods for treating synucleinopathiesCHASE THERAPEUTICS CORP·Filed 2020·Granted Jan 10, 2023·1 cites·11 claims
- 0984US10842778B2Use and composition for treating myasthenia gravis and other myasthenic syndromesDAS MG INC·Filed 2019·Granted Nov 24, 2020·1 cites·17 claims
- 1084US9744161B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Aug 29, 2017·3 cites·38 claims
- 1183US9913836B2Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Mar 13, 2018·3 cites·11 claims
- 1282US10548855B2Memantine combinations and useCHASE PHARMACEUTICALS CORP·Filed 2017·Granted Feb 4, 2020·1 cites·8 claims
- 1382US9943508B2Method and composition for treating Alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2017·Granted Apr 17, 2018·2 cites·23 claims
- 1479US11033521B2Levodopa fractionated dose composition and useAVION PHARMACEUTICALS LLC·Filed 2019·Granted Jun 15, 2021·2 cites·20 claims
- 1579US10799484B2Compositions and methods for treating synucleinopathiesCHASE THERAPEUTICS CORP·Filed 2018·Granted Oct 13, 2020·2 cites·17 claims
- 1678US10307409B2Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous systemCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Jun 4, 2019·1 cites·3 claims
- 1777US11819485B2Levodopa fractionated dose composition and useAVION PHARMACEUTICALS LLC·Filed 2022·Granted Nov 21, 2023·0 cites·44 claims
- 1877US11813248B2NK-1 antagonist compositions and methods for use in treating depressionCHASE THERAPEUTICS CORP·Filed 2022·Granted Nov 14, 2023·0 cites·5 claims
- 1977US10195187B2Oxybutynin-xanomeline transdermal therapeutic system combinationsCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Feb 5, 2019·1 cites·4 claims
- 2075US11813247B2NK-1 antagonist compositions and methods for use in treating depressionCHASE THERAPEUTICS CORP·Filed 2022·Granted Nov 14, 2023·0 cites·6 claims
- 2175US2020121656A1Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 2275US2025288545A1Neostigmine combinations and compositionsDAS MG INC·Filed 2025·Application pending·0 cites
- 2373US12023315B2Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravisDAS MG INC·Filed 2022·Granted Jul 2, 2024·0 cites·12 claims
- 2473US11318122B2Pharmaceutical combination and its use for treating synucleinopathtiesCHASE THERAPEUTICS CORP·Filed 2018·Granted May 3, 2022·1 cites·7 claims
- 2573US9896416B2Piperidinium quaternary saltsCHASE PHARMACEUTICALS CORP·Filed 2013·Granted Feb 20, 2018·1 cites·9 claims
- 2673US9044472B2Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Jun 2, 2015·1 cites·17 claims
- 2771US11896582B2Use and composition for treating myasthenia gravis and other myasthenic syndromesDAS MG INC·Filed 2020·Granted Feb 13, 2024·0 cites·5 claims
- 2871US11439613B2Levodopa fractionated dose composition and useAVION PHARMACEUTICALS LLC·Filed 2021·Granted Sep 13, 2022·0 cites·29 claims
- 2969US10149828B2Oxybutynin transdermal therapeutic system combinationCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Dec 11, 2018·1 cites·4 claims
- 3068US2021260004A1Neostigmine combination and compositionsDAS MG INC·Filed 2021·Application pending·0 cites
- 3166US12390454B2Use and composition for protection against organophosphorus poisoningCLARENCE SMITH KATHLEEN E·Filed 2022·Granted Aug 19, 2025·0 cites·23 claims
- 3265US2020253893A1Memantine combinations and useCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 3364US11389420B2Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravisDAS MG INC·Filed 2020·Granted Jul 19, 2022·0 cites·19 claims
- 3464US2020000756A1Neostigmine combination and compositionsGT BIOPHARMA INC·Filed 2018·Application pending·0 cites
- 3563US2019091214A1Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 3662US2020054611A1Use and composition for treating myasthenia gravis and other myasthenic syndromesDAS MG INC·Filed 2018·Application pending·0 cites
- 3762US2019365736A1Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 3862US2018296540A1Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2017·Application pending·0 cites
- 3962US2019314354A1Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous systemCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 4061US2020171014A1Oxybutynin-xanomeline transdermal therapeutic system combinationsCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 4159US2025329454A1Diagnostic indices for neurodegenerative conditionsCHASE THERAPEUTICS CORP·Filed 2022·Application pending·0 cites
- 4258US11752141B2Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravisDAS MG INC·Filed 2020·Granted Sep 12, 2023·0 cites·8 claims
- 4358US2019000826A1Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 4458US2013158012A1Use and composition for treating dementiaCHASE THOMAS N·Filed 2013·Application pending·0 cites
- 4557US11439630B2Use and composition for protection against organophosphorus poisoningCLARENCE SMITH KATHLEEN E·Filed 2018·Granted Sep 13, 2022·0 cites·13 claims
- 4655US2020375957A1Compositions and method for treating depressionCHASE THERAPEUTICS CORP·Filed 2018·Application pending·0 cites
- 4754US2022000854A1Domperidone antineurodegenerative combinations and useCHASE THERAPEUTICS CORP·Filed 2019·Application pending·0 cites
- 4854US2022214360A1Alpha-synuclein assaysCHASE THERAPEUTICS CORP·Filed 2020·Application pending·0 cites
- 4953US2021393595A1Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseasesCHASE THERAPEUTICS CORP·Filed 2019·Application pending·0 cites
- 5053US2023349906A1Kinases as biomarkers for neurodegenerative conditionsCHASE THERAPEUTICS CORP·Filed 2020·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Kathleen E. Clarence-Smith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →